Newsfeeds - Spark Newswire

1 minute read

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

Today, 2:21 PM

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction…

GSK

1 minute read

News

5 Value Stocks To Watch In The Healthcare Sector

By Benzinga Insights

Today, 2:21 PM

What Defines a Value Stock?

COLL

1 minute read

Analyst Ratings

Where Vir Biotechnology Stands With Analysts

By Benzinga Insights

Today, 2:21 PM

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:

VIR

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 2:21 PM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

1 minute read

Why HC Wainwright Is Bullish On This Stock’s Hepatitis-B Pipeline

By Vandana Singh

Today, 2:21 PM

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam…

ALNY

48 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 2:21 PM

During Thursday, 849 stocks hit new 52-week lows.

AADI

3 minute read

Vir Biotechnology Announces Data To Be Discussed During Today’s Hepatitis Portfolio R&D Day

By Bill Haddad

Today, 2:21 PM

– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00

VIR

1 minute read

Why Did FDA Pull Authorization For GSK-Vir’s COVID-19 Therapy? Read Here

By Vandana Singh

Today, 2:21 PM

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc’s (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment.…

GSK